Further studies to elucidate the mechanism of action of rMV-BNiP3 toward MCF-7 and MDA-MB-231 cells as well as signal pathways and their downstream molecules involved in its oncolytic activity would provide insight into the cause of its heightened response against triple negative breast cancer cells. This evidence concerns the gene BNIP3 and triple-negative breast carcinoma.